Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A (2023)
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
EJHaem, 4 (4), 1117-1131
DOI 10.1002/jha2.743, PubMed 38024633

Nyquist OE, Dalgaard J, Spetalen S, Torkildsen S, Frøen H, Galteland E, Klungsøyr O, Bergrem A, Vo C, Sørbø H, Eiken B, Lerdal H, Solvang AK, Jensvoll H, Pandzic T, Baliakas P, Dybedal I (2023)
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML
Br J Haematol (in press)
DOI 10.1111/bjh.19226, PubMed 38016923

Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F (2023)
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial
Am J Hematol (in press)
DOI 10.1002/ajh.27131, PubMed 38014779